Abstract: The present disclosure is directed to a composition for managing exaggerated sebum production in oily-prone skin, the composition containing: (1) a mixture of at least: (a) from about 0.02 to about 1% by weight of an ingredient capable of activating cannabinoid type-2 receptors (“CB2”); (b) from about 0.1 to about 3% by weight of a blend of Tetraselmis chuii and Fucus spiralis algae extracts; (c) from about 0.1 to about 4% by weight of an extract of Centella asiatica; and (d) from about 0.01 to about 0.05% by weight of an extract of Tulsi, wherein all weights are based on total weight of the composition; (2) optionally, an emulsifier; and (3) a dermatologically acceptable carrier, wherein the composition has a pH ranging from about 4.5 to about 5.5.

Abstract: A hair care composition that removes calcium fatty carboxylate salts from the hair and scalp is provided. The hair care composition includes a calcium chelant, an anionic surfactant, a hydrotrope, a carrier, and optionally a zwitterionic surfactant.

Abstract: The present invention relates to a physicochemically stable pharmaceutical composition, in a unit dose characterized in that it comprises effective amounts of 5 the active ingredients thiamine (Vitamin B1), pyridoxine (Vitamin B6), a flavonoid such as quercetin and a polyphenol such as curcumin, or their pharmaceutically acceptable salts in combination with pharmaceutically acceptable excipients, for the prevention of the formation and/or trapping of advanced glycation end products (glyoxal, methylglyoxal, Ni-carboxymethyl-iysine, N-carboxyethyl-lysine, pyrraline, pentosidine, lysine dimer, etc.), which can be used in the treatment and/or prevention of complications of diabetes mellitus (diabetic neuropathy, nephropathy and retinopathy). The pharmaceutical composition of the invention is presented orally, preferably in capsule, pill or sachet for oral administration.

Abstract: Farnesol analogs, along with their related products (e.g., treatment compositions, wipes, absorbent articles, etc.) and their methods of formation, are provided. The farnesol analog includes a hydrophilic end group (e.g., a hydroxyl end group or a carboxylic acid end group) attached to farnesol via a covalent linkage (e.g., an ester group or an ether group).

Abstract: A non-irritation, non-blurring ophthalmic sunscreen composition contains a liquid vehicle base, such as an artificial tear formulation or an ophthalmic suspension or ointment. The composition includes at least one inorganic and/or at least one organic active ingredient. The inorganic active ingredients may include, but not be limited to zinc oxide, titanium dioxide, iron oxide, zirconium oxide, and cerium oxide. The organic active ingredients may include, but not be limited to dioxybenzone, octinoxate, octisalate, homosalate, avobenzone, octocrylene, para-aminobenzoic acid, cinoxate, methyl anthranilate, octocrylene, padimate O, ensulizole, sulisobenzone, trolamine salicylate, and ecamsule.

Abstract: The invention provides methods for the treatment of myopia. The compositions preferably comprise aceclidine. The compositions optionally contain a surfactant, a viscosity agent, a polyol and/or a selective ?-2 adrenergic receptor agonist.

Abstract: The present invention is related to novel compositions comprising at least one active ingredient of the family of the triazines combined with another active ingredient and specific compounds that allow the reduction of foam formation. More particularly, the invention relates to compositions in the form of aqueous suspensions comprising a triazine, an iron complex, and one or more surfactant(s) having a particular HLB.

Abstract: Disclosed are a cosmetic composition having increased skin contact and makeup persistence and a method of manufacturing the same. The method includes: forming a powder continuous phase by rapidly mixing a powder and a film-forming agent; and obtaining a cosmetic composition in which a surface of the powder is compounded with the film-forming agent by heating the powder continuous phase for a predetermined time. In an embodiment, the cosmetic composition is manufactured by the method. In an embodiment, the cosmetic composition includes 5 wt % to 30 wt % of a powder, 0.1 wt % to 10 wt % of a film-forming agent, 10 wt % to 30 wt % of a silicone oil, and 0.1 wt % to 10 wt % of a spherical powder.

Abstract: Biopharmaceuticals, such as vaccine agents and probiotics, are encapsulated in carbohydrate-glass particles and embedded in an amorphous polymer substrate to produce polymeric compositions containing ambient-temperature stable biopharmaceuticals for syringeless administration to patients such as via dissolvable films, micro-needle patches and similar medical delivery devices. The amorphous polymer substrate is soluble in both water and a volatile organic solvent, yet the carbohydrate-glass particles are insoluble in the volatile organic solvent.

Abstract: Described herein is a shampoo composition and methods of using the same, the shampoo composition including a Class I and/or Class II chelant, a detersive surfactant, and a carrier.

Abstract: A substantially surface active agent-free foamable composition which includes short-chain alcohol, water, polymer, fatty alcohol or fatty acid or a combination of fatty alcohol and fatty acid and propellant. A substantially surface active agent-free foamable composition which includes, water, polymer, fatty alcohol or fatty acid and propellant. A method of treatment using a substantially surface active agent-free foamable compositions.

Abstract: A composition to improve hyperpigmentation is disclosed. The composition has one or more active ingredients such as tranexamic acid, niacinamide, arbutin, and Vitamin C. The composition has water, caprylic/capric triglyceride, C12-15 Alkyl Benzoate, Isononyl Isononanoate, Silica, Glyceryl Stearate and PEG-100 Stearate, Cetearyl Alcohol and Ceteareth-20, Xylitylglucoside and Anhydroxylitol and Xylitol, Hydroxyethyl Acrylate/Sodium Acryloyldimethyl Taurate Copolymer, Polysorbate 60, Phenoxyethanol and Ethylhexylglycerin, Citric Acid, Titanium Dioxide, Citrus oil, sh-Polypeptide-22, and sh-Oligopeptide-1. The composition is a non-HQ formulation that provides equal or greater efficacy with a reduced adverse reaction profile to improve skin hyperpigmentation, such as melasma, post-inflammatory hyperpigmentation, and solar lentigines. The composition reduces skin damage and provides toning to the skin.

Abstract: The present invention relates to the treatment of refractory Emotional Cognitive Disconnect (ECD) through a combination of pharmaceutical agents and therapy. Individual patients are treated with a combination of magnesium, inositol, and N-acetylcysteine along with Vitamin E, Vitamin C, zinc, biotin, alphalipoic acid and lysine as required. The compositions may be administered sequentially or simultaneously in any order and may be formulated in singular or combinatorial dosage forms.

Abstract: The invention provides compositions and methods for the treatment of presbyopia. The compositions preferably comprise aceclidine. The compositions optionally contain a surfactant and a viscosity agent.

Abstract: The invention provides compositions and methods for the treatment of presbyopia. The compositions preferably comprise aceclidine. The compositions optionally contain a surfactant and a viscosity agent.

Abstract: The present disclosure relates to the technical field of sanitary cleaning products, and more specifically to a silver ion bacteriostatic hand sanitizer and preparation method and application thereof. The silver ion bacteriostatic hand sanitizer is provided, including: 0.01˜0.03 parts by weight of silver, 0.02˜0.08 parts by weight of silver sulfate, 1˜5 parts by weight of humectant, 10˜18 parts by weight of skin conditioning agent, 0.3˜0.8 parts by weight of preservative, 0.1˜0.5 parts by weight of sodium dodecyl benzene sulfonate, 0.8˜1.8 parts by weight of ethylhexylglycerol, 1˜5 parts by weight of propylene glycol, 3˜6 parts by weight of NONOXYNOL-14, 1˜6 parts by weight of PEG-50 castor oil, 0.01˜0.05 parts by weight of flavor and 80˜120 parts by weight of deionized water. The silver ion bacteriostatic hand sanitizer has the advantages of high-efficiency bacteriostasis, sterilization and itching relief, mild performance and no stimulation, and keeps the hands moisturized.

Abstract: Described herein is a shampoo composition and methods of using the same, the shampoo composition including a copper chelant, a detersive surfactant, and a carrier.

Abstract: The present disclosure relates to anhydrous cosmetic composition comprising hydrophobic silica particles, PMMA particles, silicone oil, hydrocarbon oil, silicone elastomer and silicone emulsifier.

Abstract: Compositions and methods for the treatment of onychomycosis. The compositions include a pharmaceutically effective amount of one or more anti-fungal agents in a petrolatum carrier. The one or more anti-fungal agents may include, for example, terbinafine HCl, ciclopirox, ciclopirox olamine, fluconazole, itraconazole, ketoconazole, amorolfine, efinaconazole, clotrimazole, miconazole (miconazole nitrate), and any combination thereof.

Abstract: Compositions and methods for the treatment of onychomycosis. The compositions include a pharmaceutically effective amount of polyhexamethylene biguanide (PHMB), polyaminopropyl biguanide (PAPB), and/or chlorhexidine (CHG) in a petrolatum carrier.